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High-Flow Oxygen Therapy in Infants with Bronchiolitis
To the Editor: In the article by Franklin et al. 
(March 22 issue),1 in which infants with bron-
chiolitis were assigned to receive low-flow oxygen 
(standard-therapy group) or high-flow oxygen 
(high-flow group) through a nasal cannula, the 
primary outcomes differed between groups. Treat-
ment failure in the standard-therapy group allowed 
patients to be placed in the high-flow group, 
whereas failure in the high-flow group resulted 
in unknown interventions beyond transfer to an 
intensive care unit (ICU). In addition, other mea-
sures of failure (such as transfer or intubation) 
did not favor the use of high-flow therapy.
Standard therapy worked well in 566 patients, 
suggesting that a large number of patients in the 
high-flow group may not have required its use. 
The use of high-flow therapy in such patients 
increases cost without a clear benefit. Escalation 
of therapy in the high-flow group occurred at 
significantly higher respiratory rates, suggesting 
that provider discomfort with modest levels of 
tachypnea drove the escalation of care in the 
low-flow group. In addition, in both groups, ap-
proximately the same number of patients who 
received high-flow therapy did not benefit, which 
implies that there is no real advantage in initi-
ating high-flow therapy early rather than post-
poning it until after standard therapy has failed. 
Although high-flow therapy may help some pa-
tients with bronchiolitis and hypoxemia, it is 
premature to assume that it should be used 
universally.
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To the Editor: It is worth reflecting on the ef-
ficiency of high-flow therapy. On the basis of the 
authors’ primary outcome, efficacy would be a 
number needed to treat of 9 patients to prevent 
an infant’s condition from worsening given that 
all secondary outcomes were equal. Therefore, 
efficiency would depend only on the cost differ-
ence between high-flow and low-flow therapy. 
Using the probabilities reported by the authors 
(Fig. 1), we created a decision-analysis tree and 
have concluded that the best approach would be 
to initially use low-flow therapy and to use high-
flow therapy only after low-flow therapy has 
failed (expected cost, $19.03 per patient).
The difference in the cost of disposable items 
alone is $60.07 ($79.10 vs. $19.03), and the dif-
ference in benefit1,2 is 11% (95% confidence in-
terval [CI], 15 to 7). Therefore, the incremental 
cost-effectiveness ratio (ICER) to prevent worsen-
ing would be as follows: ICER = cost difference/
benefit difference = $60.07/0.11 = $546.09 (95% 
CI, 400.47 to 858.14).
Cost might increase if devices had to be pur-
chased ($2,613.45 per device) or alternative brands 
used. In conclusion, considering the elevated cost 
of high-flow therapy, we believe it is necessary 
to study its efficiency rigorously before general-
izing its use.
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To the Editor: Franklin et al. reported lower 
rates of escalation of care due to treatment fail-
ure in infants with bronchiolitis receiving high-
flow oxygen than in those receiving standard 
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treatment. There was no significant difference 
between groups on admission to the ICU. The 
authors stated that all 167 infants in the stan-
dard-therapy group who had escalation of care, 
including 65 in whom high-flow oxygen therapy 
was ineffective, were admitted to an ICU. How-
ever, different data for ICU admission (65 of 167) 
are shown in Table 3 of the article (available at 
NEJM.org). The statistical difference between 
groups for this important clinical parameter is 
probably destined to change according to the 
“true” number of patients to consider.
It is also quite surprising that children who 
received high-flow oxygen therapy had a higher 
respiratory rate (62.6 breaths per minute) than 
those in the standard-treatment group (54.6 
breaths per minute) at the time of escalation of 
care. There was no significant difference in re-
spiratory rate between the two groups at base-
line (53.1 vs. 52.0), and an increase in respira-
tory rate by any amount since admission was one 
of the clinical criteria for escalation of care. The 
authors do not explain this point.
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To the Editor: Franklin et al. show that high-
flow oxygen therapy is successful in preventing 
escalation of care in infants with bronchiolitis. 
A word of caution regarding escalation of care 
in the standard-therapy group is indicated, since 
escalation most often resulted in the initiation 
of the comparator, high-flow oxygen therapy. Pre-
vention of admission to the pediatric intensive 
care unit (PICU) and of mechanical ventilation 
are more relevant end points, since both are as-
sociated with substantial complications and high 
costs.1-3 High-flow oxygen use may add to the 
Figure 1. Decision-Tree Analysis — Model and Roll-Back Outcome.
The treatment cost of disposable items per patient is as follows: high‑flow nasal cannula (HFNC), $79.10 (Fisher 
and Paykel), including $32.07 per interface and $47.03 per circuit, and low‑flow nasal cannula (LFNC), $0.84 (Inter‑
surgical). The cost per patient of putting every patient initially on low‑flow therapy and escalating to high‑flow therapy 
only after low‑flow therapy has failed is $19.03. The pink line indicates the preferred decision, which is associated 
with lower costs, and the short parallel marks indicate the more expensive and therefore less preferable decision. 
Cost data were obtained from the National Health Service Supply Chain, April 2018.
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alarming increase in PICU admissions for viral 
bronchiolitis.3 A trend that is confirmed by pre-
liminary data from the Netherlands in a 10-year 
national PICU registry showed an increase in 
admissions (Fig. 2). Ironically, as compared with 
the standard-therapy group, more children in the 
high-flow oxygen group required PICU admis-
sion (65 vs. 87, P = 0.08) and intubation (4 vs. 8). 
We suggest that trials that evaluate interventions 
in viral bronchiolitis use PICU admission and in-
vasive mechanical ventilation as distinct primary 
outcomes.
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The authors reply: Our study was designed to 
investigate whether high-flow oxygen can be safe-
ly used in general wards, with escalation of care 
due to treatment failure as a primary end point. 
For pragmatic reasons, patients in the standard-
therapy group were allowed to cross over to the 
high-flow group for rescue therapy. Infants 
whose condition did not improve in response to 
high-flow oxygen therapy were routinely admit-
ted to the ICU, whereas those who did not have a 
response to standard therapy could be treated on 
general wards with high-flow oxygen therapy.
In response to Meskill and Moore: we agree 
that care for the majority of children with bron-
chiolitis can be managed with standard therapy. 
The study was neither powered nor designed to 
determine whether late commencement of high-
flow therapy is inferior to early commencement.
De Benedictis and Cogo question the ICU 
admission data in the standard-therapy group. 
In this group, all 167 patients with treatment 
failure who required escalation of therapy were 
not automatically admitted to the ICU (65 pa-
tients were admitted). In the high-flow group, 
87 were admitted to the ICU. Further, in an un-
blinded study, we cannot exclude the possibility 
of a greater bias to tolerate sicker infants in the 
high-flow group, which would explain the high-
er respiratory rate at the point of escalation.
Modesto i Alapont et al. are correct that an 
understanding of the comparative costs will be an 
important consideration in treatment decisions. 
An analysis of health care–related economics is 
ongoing.
Our study showed that the use of high-flow 
oxygen therapy in infants with bronchiolitis can 
be accomplished in the general ward. The most 
appropriate timing of its deployment remains to 
be clarified.
Linssen et al. comment on the upward trend 
of bronchiolitis-related ICU admissions in the 
Netherlands, which is consistent with previously 
published registry data from Australia and New 
Zealand.1 In the past, high-flow therapy was 
largely restricted to the ICU. Our large random-
ized, controlled trial demonstrates excellent safe-
ty when applying high-flow therapy to hypox-
emic infants with bronchiolitis outside ICUs. In 
our study, 308 of 13,454 (2.3%) infants with 
bronchiolitis were admitted to ICUs (156 infants 
before enrollment and 152 after enrollment). 
Figure 2. Increase in PICU Admissions in the Netherlands from 2006 
through 2016.
Data were extracted from a national pediatric intensive care unit (PICU) 
registry that reported PICU admissions in which a diagnosis of primary  
or secondary bronchiolitis was reported.
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Among the 1472 infants who were randomly as-
signed to the study, 12 (0.8%) were intubated, a 
rate that is lower than that previously reported 
by Hasegawa et al. (2.3%).2 The latest figures 
provided in the Australia and New Zealand reg-
istry show a decrease in ICU admissions (Fig. 3), 
possibly because of more frequent use of high-
flow oxygen in general wards. We disagree that 
ICU care should be used as the primary out-
come, since ICU admission depends not only on 
the physiological status of the patient but also 
on local thresholds and practices. Risk-adjusted 
intubation rates that varied by a factor of 6 were 
reported in infants with bronchiolitis who were 
admitted to ICUs in Australia and New Zealand.3
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Are We Prepared for Nuclear Terrorism?
To the Editor: Gale and Armitage (March 29 
issue)1 provide detailed scenarios of intentional 
exposure of the public to ionizing radiation. Such 
an incident of any size would be a disaster, and 
the detonation of an improvised nuclear device 
would be catastrophic. The authors wisely note 
the importance of efforts to avoid these incidents 
and the need for education, prevention, prepared-
ness, planning, and necessary resources.
After the 9/11 World Trade Center and an-
thrax terrorist attacks in 2001, the U.S. govern-
ment and many nongovernmental organizations 
launched a concerted effort to develop resources 
and capabilities based on advances in science and 
technology. Key resources include the Radiation 
Emergency Medical Management website (www . 
remm . nlm . gov/ ), which offers medical care pro-
viders information on response and prepared-
ness, just-in-time training, educational materials, 
and links to other organizations’ resources for 
first responders.
Many programs are run by staff members 
who continue to work every day on this massive 
task of preparedness to respond to a radiologic 
disaster. Health care workers and response plan-
ners must endeavor to work together without 
being overwhelmed by the task at hand.
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Figure 3. ICU Admissions for Infants with Bronchiolitis in Australia  
and New Zealand between 2010 and 2017.
Data are from the Australian and New Zealand Pediatric Intensive Care 
(ANZPIC) Registry.1
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